Takeda Pharmaceutical Company Limited

Yoshihisa Nakada

Masato Yoshikawa

Morihisa Saitoh

Tomohiro Seki

Masaki Seto

Akito Shibuya

Zenyu Shiokawa

Michiyo Mochizuki

Yusuke Tominari

Kosuke Hidaka

Yayoi Nakayama

Yasuo Nakagawa

Taisuke Kato

Tsuneo Oda

Yusuke Sasaki

Paul D Greenspan

Brian Scott Freeze

Yasufumi Wada

Taisuke Tawaraishi

Shumpei Murata

Yusuke Ohba

Atsutoshi Okabe

Masami Yamada

Ikuo Fujimori

Taku Kamei

Masanori Okaniwa

Nobuki Sakauchi

Tetsuya Tsukamoto

Tomoya Yukawa

Nobuyuki Matsunaga

Yuji Ishichi

Hideyuki Nakagawa

Takatoshi Yogo

Taisuke Katoh

Yayoi Yoshitomi

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

Antibody-drug conjugates comprising a cyclic dinucleotide

Cyclic dinucleotide

The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.

Heterocyclic compounds

The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like. An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.

Heterocyclic derivative and use thereof

Growing community of inventors

Fujisawa Kanagawa, Japan

Yoshihisa Nakada